Axsome Therapeutics Sets Terms for IPO
Axsome Therapeutics expects to price more than 4 million shares in the range of $11 to $13 in an IPO valued up to more than $63 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 238
Ellipse Technologies Prepares for IPO
The IPO for Ellipse Technologies, a medical technology company focused on revolutionizing orthopedic surgery, is valued up to $75 million.
4 Key FDA Decisions Expected in November and December
24/7 Wall St. has collected several big FDA decisions coming up in the month of November.
6 BioPharma Movers That Cannot Be Ignored
Last week, a few biotech companies made absolutely massive runs, and some had serious falls.
Medical Tourism Expected to Triple by 2019
Medical tourism has become increasingly popular in recent years as we see the globalization of modern medicine take off, as well as the continued improvement in health care systems within developing nations.
Voyager Therapeutics Sets Terms for IPO
Voyager Therapeutics intends to offer roughly 4.7 million shares within the range of $15 to $17 apiece in an IPO valued up to more than $91 million.
Is Mylan’s Topline Growth Enough for Investors?
Mylan reported better-than-expected third-quarter financial results before the markets opened on Friday.
AbbVie Soars on Solid Earnings and Guidance
AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.
What to Expect From Mylan Earnings
Mylan is scheduled to release its third-quarter financial results before the markets open on Friday.
What to Look For in AbbVie Earnings
AbbVie is expected to report its third-quarter financial results before the markets open on Friday.
Abiomed Beats on Estimates, but Was It by Enough?
Abiomed reported better-than-expected fiscal second-quarter financial results before the markets opened on Thursday.
Kura Oncology Gears Up for IPO With Updated Terms
Kura Oncology is offering $60 million worth of shares in its initial public offering at an expected $16 per share.
What a Combined Allergan and Pfizer Might Actually Look Like
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
These Chinese Biotechs Are Severely Undervalued
Those who remember the bursting of the tech bubble at the turn of the millennium may have the nagging feeling that something vaguely similar, though on a smaller scale, just happened with biotech.
6 Top Specialty Pharmaceutical Stocks to Buy With Over 100% Upside Potential
24/7 Wall St. screened the RBC specialty pharmaceutical universe and found six companies rated Outperform with over 100% upside to the firm's price target.